Latest filings (excl ownership)
DEFM14A
Proxy related to merger
23 Jan 24
PREM14A
Preliminary proxy related to merger
12 Jan 24
15-12G
Securities registration termination
4 Jan 24
8-K
Entry into a Material Definitive Agreement
22 Dec 23
EFFECT
Notice of effectiveness
4 Dec 23
POS AM
Prospectus update (post-effective amendment)
30 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
30 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Cost Associated with Exit or Disposal Activities
2 Oct 23
8-K
Termination of a Material Definitive Agreement
15 Sep 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Other Events
25 Jul 23
25-NSE
Exchange delisting
19 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
10 Apr 23
8-K
Departure of Directors or Certain Officers
10 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
18 Jan 23
8-K
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
6 Dec 22
8-K
Cost Associated with Exit or Disposal Activities
30 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
SQZ Biotechnologies Announces Leadership Transition
6 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
11 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 22
8-K
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
31 May 22
8-K
Regulation FD Disclosure
19 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
10-K
2021 FY
Annual report
16 Mar 22
8-K
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
24 Jan 22
8-K
Other Events
9 Dec 21
8-K
Other Events
2 Dec 21
Latest ownership filings
SC 13G/A
AMERICAN INTERNATIONAL GROUP, INC.
13 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
4
PATRICK V.J.J. VINK
15 Jun 23
4
Sapna Srivastava
15 Jun 23
4
AMY W SCHULMAN
15 Jun 23
4
MARC SCHEGERIN
15 Jun 23
4
Klavs F. Jensen
15 Jun 23
4
Pushkal Garg
15 Jun 23
4
Marc Elia
15 Jun 23
4
Bernard Coulie
15 Jun 23
4
PAUL BOLNO
15 Jun 23
SC 13G/A
683 Capital Management, LLC
14 Feb 23
SC 13G/A
AMERICAN INTERNATIONAL GROUP, INC.
14 Feb 23
SC 13G/A
NanoDimension II Management Ltd
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
4
Richard Capasso
26 Jan 23
4
Marshelle Smith Warren
26 Jan 23
4
Lawrence J Knopf
26 Jan 23
4
David First
26 Jan 23
4
HOWARD PHD MD BERNSTEIN
26 Jan 23
4
Richard Capasso
16 Aug 22
4
Micah Zajic
13 Jul 22
4
Armon Sharei
5 Jul 22
4
Lawrence J Knopf
5 Jul 22
4
Richard Capasso
5 Jul 22
4
AMY W SCHULMAN
16 Jun 22
4
Pushkal Garg
16 Jun 22
4
PAUL BOLNO
16 Jun 22
4
PATRICK V.J.J. VINK
16 Jun 22
4
Sapna Srivastava
16 Jun 22
4
Klavs F. Jensen
16 Jun 22
4
MARC SCHEGERIN
16 Jun 22
4
Bernard Coulie
16 Jun 22
4
Marc Elia
16 Jun 22
4
Marshelle Smith Warren
3 Jun 22
3
Marshelle Smith Warren
3 Jun 22
4
Klavs F. Jensen
27 May 22
4
David First
15 Feb 22
4
Micah Zajic
15 Feb 22
4
Richard Capasso
15 Feb 22